The effects of laropiprant, a selective prostaglandin D₂ receptor 1 antagonist, on the antiplatelet activity of clopidogrel or aspirin

Author： Dallob Aimee Luo Wen-Lin Luk Julie Mabalot Ratcliffe Lisa Johnson-Levonas Amy O. Schwartz Jules I. Dishy Victor Kraft Walter K. De Hoon Jan N. Van Hecken Anne De Lepeleire Inge Radziszewski Waldemar Wagner John A. Lai Eseng

Publisher： Informa Healthcare

ISSN： 1369-1635

Source： Platelets, Vol.22, Iss.7, 2011-11, pp. : 495-503

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Antiplatelet and Anticoagulant Effects of ''HN-11 500,'' a Selective Thromboxane Receptor Antagonist

By Schenk J.F. Radziwon P. Fellier H. Breddin H.K.

Thrombosis Research, Vol. 103, Iss. 2, 2001-07 ,pp. : 79-91

Elsevier

Access to resources Recommend Favorite

Incidence of side-effects of dual antiplatelet therapy with clopidogrel and aspirin after coronary stent implantation

By Ohkubo Kenji

Cardiovascular Intervention and Therapeutics, Vol. 26, Iss. 1, 2011-01 ,pp. : 33-37

Springer Publishing Company

Access to resources Recommend Favorite

Inhibition of platelet aggregation by prostaglandin E1 (PGE1) in diabetic patients during therapy with clopidogrel and aspirin

By Kreutz Rolf P. Nystrom Perry Kreutz Yvonne Miao Jia Kovacs Richard Desta Zeruesenay Flockhart David A. Jin Yan

Platelets, Vol. 24, Iss. 2, 2013-03 ,pp. : 145-150

Informa Healthcare

Access to resources Recommend Favorite

The Antiplatelet Aggregation Effects of Aspirin Suppositories

Cerebrovascular Diseases, Vol. 16, Iss. 1, 2003-05 ,pp. : 31-35

Karger

Access to resources Recommend Favorite

Effects of clopidogrel on “aspirin specific” pathways of platelet inhibition

By Hobson Alex Qureshi Zeshan Banks Phil Curzen Nick

Platelets, Vol. 20, Iss. 6, 2009-09 ,pp. : 386-390

Informa Healthcare

Access to resources Recommend Favorite